Status:
COMPLETED
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Anemia
Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether giving darbepoetin ...
Detailed Description
OBJECTIVES: Primary \* To compare the effects of IV iron, oral iron, or placebo in combination with darbepoetin alfa on the hematopoietic response rate, defined as a hemoglobin increment of ≥ 2.0 g/...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of a non-myeloid cancer (other than non-melanomatous skin cancer)
- Receiving or scheduled to receive chemotherapy (biological agents, such as small molecules/tyrosine kinase inhibitors and antibody-based therapies, are allowed)
- Has chemotherapy-related anemia (hemoglobin \< 11 g/dL)
- No anemia known to be secondary to gastrointestinal bleeding or hemolysis
- No anemia known to be secondary to vitamin B12 or folic acid deficiency
- \+ Vitamin B12 and folic acid deficiency must be ruled out if the mean corpuscular volume (MCV) is \> 100 fL
- No anemia secondary to chemotherapy-induced myelodysplastic syndromes
- No primary hematologic disorder causing moderate to severe anemia (e.g., congenital dyserythropoietic anemia, homozygous hemoglobin S disease or compound heterozygous sickling states, or thalassemia major)
- \- Carriers for these disease states are eligible
- No first-degree relative with primary hemochromatosis (unless the patient has undergone HFE genotyping and was found to have at least one wild-type allele, while the proband in the family demonstrated to have either the common C282Y or H63D mutation)
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Ferritin \> 20 mcg/L (i.e., not obviously iron deficient)
- ALT or AST \< 5 times upper limit of normal
- Alert, mentally competent, and able to sign informed consent
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- Willing or able to be randomized and undergo study treatment
- Willing or able to fill out quality-of-life forms
- No uncontrolled hypertension (i.e., systolic blood pressure \[BP\] ≥ 180 mm Hg or diastolic BP ≥ 100 mm Hg)
- No history of uncontrolled cardiac arrhythmias
- No pulmonary embolism or deep venous thrombosis within the past year (unless the patient is on anticoagulation therapy and planning to continue it during study participation)
- No known hypersensitivity to darbepoetin alfa, erythropoietin, mammalian cell-derived products, iron, or human albumin
- No seizures within the past 3 months
- No gastrointestinal conditions expected to cause significant impairment of oral iron, such as untreated celiac disease or amyloidosis involving the gut - Patients with celiac disease who are adhering to a gluten-free diet are eligible
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 3 months since prior darbepoetin alfa, epoetin alfa, or any investigational forms of erythropoietin (e.g., gene-activated erythropoietin or novel erythropoiesis-stimulating protein)
- More than 1 year since prior peripheral blood stem cell or bone marrow transplantation
- More than 2 weeks since prior red blood cell transfusions
- More than 14 days since prior major surgery
- No prior gastrectomy or resection of \> 100 cm of small intestine
- Not planning to undergo stem cell or bone marrow transplantation within the next 6 months
Exclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
502 Patients enrolled
Trial Details
Trial ID
NCT00661999
Start Date
January 1 2006
End Date
March 1 2009
Last Update
May 17 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
2
Mayo Clinic
Rochester, Minnesota, United States, 55905